IL6 and hemophagocytic syndrome: Ruxolitinib administration improved survival and physiological parameters in murine models of HLH, decreased levels of phosphorylated STAT1 in peripheral blood white blood cells, decreased serum levels of IL-6, TNF-α, MCP-1, CXCL10, and soluble IL-2 receptor, and reduced tissue infiltration (57).